Precision therapy for solid tumors targeting CDK4/6 and VEGF
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a combination of two targeted drugs for advanced solid tumors like colorectal, lung, breast, and genitourinary cancers. The goal is to see if blocking certain proteins and a long RNA molecule can slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be of white ethnicity.
- You must be at least 18 years old.
- You must have a diagnosis of colorectal, lung, genitourinary, or breast cancer that is stage III or IV (with or without spread to lymph nodes or distant organs).
- You cannot have a history of other cancers that have come back or spread.
- You cannot have certain health conditions like inflammatory bowel disease, heart disease, autoimmune disease, diabetes, high blood pressure, neurological disorders, active infections, or a body mass index (BMI) over 30.
- You must not be pregnant or have had significant weight loss or surgeries recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
This study is looking at whether people with certain gastrointestinal cancers who have had a very good response to targeted therapy or immunotherapy might be able to avoid surgery for now and instead be closely monitored. The goal is to see if this non-surgical approach is safe and effective.
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
This study is testing an investigational drug called SG1827, either alone or combined with other standard immunotherapy medicines, for advanced solid tumors. The goal is to see if this combination can help shrink or slow the growth of the tumor.
This trial tests two pills (pazopanib and palbociclib) together for people with advanced solid tumors that have a specific gene change (11q13 amplification) and have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.